

Laurent Cotte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4341595/publications.pdf>

Version: 2024-02-01

83
papers

5,126
citations

201385

27
h-index

88477

70
g-index

83
all docs

83
docs citations

83
times ranked

5461
citing authors

#	ARTICLE	IF	CITATIONS
1	Progressive multifocal leukoencephalopathy in patients with immunovirological control and at least 6â€‘months of combination antiretroviral therapy. <i>Aids</i> , 2022, 36, 539-549.	1.0	3
2	High syphilis prevalence and incidence in people living with HIV and Preexposure Prophylaxis users: A retrospective review in the French Dataâ€™AIDS cohort. <i>PLoS ONE</i> , 2022, 17, e0268670.	1.1	6
3	Prevalence and Incidence of Human Papillomavirus Infection in Men Having Sex With Men Enrolled in a Pre-exposure Prophylaxis Study: A Sub-study of the Agence Nationale de Recherches sur le SIDA et les HÃ©patites Virales â€‘Intervention PrÃ©ventive de lâ€™Exposition aux Risques avec et pour les hommes Gaysâ€™ Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, 41-49.	2.9	8
4	No barrier to care, yet disparities in the HIV care continuum in France: a nationwide population study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1573-1579.	1.3	2
5	Inflammatory Markers During Early Treatment of Seroconverters in a Randomized Placebo-Controlled Trial of PrEP (ANRS-IPERGAY). <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab085.	0.4	0
6	Forgiveness of Dolutegravir-Based Triple Therapy Compared With Older Antiretroviral Regimens: A Prospective Multicenter Cohort of Adherence Patterns and HIV-RNA Replication. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab316.	0.4	18
7	Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2675-2680.	1.3	6
8	Dramatic decline in new HIV diagnoses in persons born in France in a large nationwide HIV cohort. <i>Public Health</i> , 2021, 196, 129-134.	1.4	1
9	Quantifying transmission dynamics of acute hepatitis C virus infections in a heterogeneous population using sequence data. <i>PLoS Pathogens</i> , 2021, 17, e1009916.	2.1	6
10	Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012â€‘2018. <i>Clinical Infectious Diseases</i> , 2021, 73, e3266-e3274.	2.9	8
11	Optimizing Strategies for Chlamydia trachomatis and Neisseria gonorrhoeae Screening in Men Who Have Sex With Men: A Modeling Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 1966-1972.	2.9	7
12	Reaching the Second and Third Joint United Nations Programme on Human Immunodeficiency Virus (HIV)/AIDS 90-90-90 Targets Is Accompanied by a Dramatic Reduction in Primary HIV Infection and in Recent HIV Infections in a Large French Nationwide HIV Cohort. <i>Clinical Infectious Diseases</i> , 2020, 71, 293-300.	2.9	14
13	Early diagnosis and risk factors of acute hepatitis C in high-risk MSM on preexposure prophylaxis. <i>Aids</i> , 2020, 34, 47-52.	1.0	18
14	On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. <i>Lancet HIV</i> , 2020, 7, e113-e120.	2.1	54
15	Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection. <i>Aids</i> , 2020, 34, 493-500.	1.0	10
16	Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1324-1331.	1.3	6
17	Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate â€‘ emtricitabine for HIV preâ€‘exposure prophylaxis. <i>Journal of the International AIDS Society</i> , 2020, 23, e25420.	1.2	13
18	Elvitegravirâ€‘Cobicistatâ€‘Emtricitabineâ€‘Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2019, 70, 943-946.	2.9	4

#	ARTICLE	IF	CITATIONS
19	Trends in the risk of myocardial infarction among HIV-1-infected individuals relative to the general population in France: Impact of gender and immune status. PLoS ONE, 2019, 14, e0210253.	1.1	11
20	Community-Based Care in the ANRS-IPERGAY Trial: The Challenges of Combination Prevention. AIDS Education and Prevention, 2019, 31, 259-272.	0.6	4
21	THU-142-Sofosbuvir + velpatasvir + voxilaprevir in DAA failure patients with cirrhosis: Final results of the French compassionate use program. Journal of Hepatology, 2019, 70, e224.	1.8	4
22	Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection. PLoS ONE, 2019, 14, e0215464.	1.1	17
23	Patterns of Hepatitis C Virus Transmission in Human Immunodeficiency Virus (HIV)-infected and HIV-negative Men Who Have Sex With Men. Clinical Infectious Diseases, 2019, 69, 2127-2135.	2.9	50
24	Successful treatment with anakinra of an HIV-associated immune reconstitution inflammatory syndrome mimicking adult-onset Still's disease. Rheumatology, 2019, 58, 363-365.	0.9	4
25	Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV. Aids, 2018, 32, 1077-1082.	1.0	50
26	Factors associated with partner notification of STIs in men who have sex with men on PrEP in France: a cross-sectional substudy of the ANRS-IPERGAY trial. Sexually Transmitted Infections, 2018, 94, 490-493.	0.8	7
27	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV, 2018, 5, e211-e220.	2.1	108
28	Costs and benefits of on-demand HIV preexposure prophylaxis in MSM. Aids, 2018, 32, 95-102.	1.0	31
29	Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infectious Diseases, 2018, 18, 308-317.	4.6	175
30	Effect of On-Demand Oral Pre-exposure Prophylaxis With Tenofovir/Emtricitabine on Herpes Simplex Virus-1/2 Incidence Among Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Trial. Open Forum Infectious Diseases, 2018, 5, ofy295.	0.4	9
31	Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trial. Aids, 2018, 32, 2353-2361.	1.0	10
32	Hepatitis C virus incidence in HIV-infected and in preexposure prophylaxis (PrEP)-using men having sex with men. Liver International, 2018, 38, 1736-1740.	1.9	57
33	The ANRS-Ipergay trial, an opportunity to use qualitative research to understand the perception of the participant-physician relationship. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 41-47.	0.6	5
34	Hepatitis C virus spread from HIV-positive to HIV-negative men who have sex with men. PLoS ONE, 2018, 13, e0190340.	1.1	62
35	Smoking-associated morbidities on computed tomography lung cancer screens in HIV-infected smokers. HIV Medicine, 2017, 18, 787-789.	1.0	4
36	Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - a route for eradication?. Journal of Infection, 2017, 75, 234-241.	1.7	17

#	ARTICLE	IF	CITATIONS
37	Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. <i>Lancet HIV</i> , 2017, 4, e402-e410.	2.1	379
38	Epidemiology of autoimmune and inflammatory diseases in a French nationwide HIV cohort. <i>Aids</i> , 2017, 31, 2159-2166.	1.0	39
39	Sub-Saharan African migrants have slower initial CD4+ cell recovery after combined antiretroviral treatment initiation than French natives. <i>Aids</i> , 2017, 31, 1323-1332.	1.0	4
40	Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study. <i>PLoS ONE</i> , 2017, 12, e0187517.	1.1	9
41	Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination. <i>BMC Medicine</i> , 2017, 15, 217.	2.3	27
42	Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study. <i>PLoS ONE</i> , 2017, 12, e0170661.	1.1	39
43	From first-generation hepatitis C virus protease inhibitors to direct-acting antivirals. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 733-734.	0.8	3
44	Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV and hepatitis C virus coinfecting patients treated with boceprevir or telaprevir-based therapy. <i>Aids</i> , 2016, 30, 2085-2090.	1.0	0
45	Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naïve HIV patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3235-3241.	1.3	1
46	Hepatitis C treatment initiation in HIV-HCV coinfecting patients. <i>BMC Infectious Diseases</i> , 2016, 16, 345.	1.3	8
47	Telaprevir enhances ribavirin-induced anaemia through renal function impairment. <i>Antiviral Therapy</i> , 2015, 20, 479-486.	0.6	5
48	Perception of Antiretroviral Generic Medicines: One-Day Survey of HIV-Infected Patients and Their Physicians in France. <i>PLoS ONE</i> , 2015, 10, e0117214.	1.1	24
49	Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort. <i>PLoS ONE</i> , 2015, 10, e0133358.	1.1	15
50	Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfecting Patients. <i>PLoS ONE</i> , 2015, 10, e0141164.	1.1	33
51	No Perinatal HIV-1 Transmission From Women With Effective Antiretroviral Therapy Starting Before Conception. <i>Clinical Infectious Diseases</i> , 2015, 61, civ578.	2.9	180
52	On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2237-2246.	13.9	1,302
53	Persistent Production of an Integrase-Deleted HIV-1 Variant with No Resistance Mutation and Wild-Type Proviral DNA in a Treated Patient. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 142-149.	0.5	5
54	Acceptability and confidence in antiretroviral generics of physicians and HIV-infected patients in France. <i>Journal of the International AIDS Society</i> , 2014, 17, 19608.	1.2	4

#	ARTICLE	IF	CITATIONS
55	Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4). <i>International Journal of Epidemiology</i> , 2014, 43, 1425-1436.	0.9	70
56	Is impaired kidney function an independent predictor of the risk of myocardial infarction in HIV-infected individuals?. <i>Aids</i> , 2014, 28, 1987-1989.	1.0	0
57	Telaprevir for HIV/Hepatitis C Virus-Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 Telaprevir): An Open-Label, Single-Arm, Phase 2 Trial. <i>Clinical Infectious Diseases</i> , 2014, 59, 1768-1776.	2.9	25
58	Comparison of renal changes with lopinavir/ritonavir plus raltegravir or tenofovir/emtricitabine in the PROGRESS study. <i>Future Virology</i> , 2014, 9, 707-714.	0.9	0
59	Is Intrapartum Intravenous Zidovudine for Prevention of Mother-to-Child HIV-1 Transmission Still Useful in the Combination Antiretroviral Therapy Era?. <i>Clinical Infectious Diseases</i> , 2013, 57, 903-914.	2.9	113
60	HIV Replication and Immune Status Are Independent Predictors of the Risk of Myocardial Infarction in HIV-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2012, 55, 600-607.	2.9	141
61	Discordance in HIV-1 Co-receptor use prediction by different genotypic algorithms and phenotype assay: Intermediate profile in relation to concordant predictions. <i>Journal of Medical Virology</i> , 2012, 84, 402-413.	2.5	12
62	The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: A case control study. <i>Journal of Hepatology</i> , 2011, 54, 489-496.	1.8	44
63	Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. <i>Aids</i> , 2010, 24, 1228-1230.	1.0	256
64	Predictors of Loss of Virologic Response in Subjects Who Simplified to Lopinavir/Ritonavir Monotherapy from Lopinavir/Ritonavir Plus Zidovudine/Lamivudine. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 269-275.	0.5	20
65	Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug-Resistant HIV-1-Infected Patients: A Randomized Open-Label Trial. <i>Clinical Infectious Diseases</i> , 2009, 49, 1259-1267.	2.9	57
66	Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms. <i>Journal of Medical Virology</i> , 2009, 81, 672-677.	2.5	18
67	Natural polymorphisms in HIV-1 protease: Impact on effectiveness of a first-line lopinavir-containing antiretroviral therapy regimen. <i>Journal of Medical Virology</i> , 2008, 80, 1871-1879.	2.5	12
68	Expected response to protease inhibitors of HIV-1 non-B subtype viruses according to resistance algorithms. <i>Aids</i> , 2008, 22, 1087-1089.	1.0	13
69	Population Pharmacokinetics of Tenofovir in AIDS Patients. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 1282-1288.	1.0	34
70	Changes in the Peripheral Blood mtDNA Levels in Naive Patients Treated by Different Nucleoside Reverse Transcriptase Inhibitor Combinations and Their Association with Subsequent Lipodystrophy. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 54-61.	0.5	9
71	Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores. <i>Aids</i> , 2007, 21, 2245-2248.	1.0	9
72	Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. <i>Aids</i> , 2003, 17, 2479-2486.	1.0	477

#	ARTICLE	IF	CITATIONS
73	Role of Long-Term Nucleoside-Analogue Therapy in Lipodystrophy and Metabolic Disorders in Human Immunodeficiency Virus-Infected Patients. <i>Clinical Infectious Diseases</i> , 2002, 34, 649-657.	2.9	106
74	Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. <i>Blood</i> , 2001, 98, 906-912.	0.6	349
75	Trial of oral fumagillin for the treatment of intestinal microsporidiosis in patients with HIV infection. <i>Aids</i> , 2000, 14, 1341-1348.	1.0	62
76	Reply. <i>Journal of Infectious Diseases</i> , 2000, 182, 381-381.	1.9	0
77	Waterborne Outbreak of Intestinal Microsporidiosis in Persons with and without Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 1999, 180, 2003-2008.	1.9	180
78	INTESTINAL MICROSPORIDIOSIS OCCURRING IN TWO RENAL TRANSPLANT RECIPIENTS TREATED WITH MYCOPHENOLATE MOFETIL. <i>Transplantation</i> , 1999, 68, 699-701.	0.5	78
79	Detection of <i>Pneumocystis carinii</i> DNA in Blood Specimens from Human Immunodeficiency Virus-Infected Patients by Nested PCR. <i>Journal of Clinical Microbiology</i> , 1999, 37, 127-131.	1.8	27
80	Effect of Parenteral Medium and Long-Chain Triglycerides on Lymphocytes Subpopulations and Functions in Patients With Acquired Immunodeficiency Syndrome: A Prospective Study. <i>Journal of Parenteral and Enteral Nutrition</i> , 1998, 22, 67-71.	1.3	27
81	Potential efficacy of fumagillin in intestinal microsporidiosis due to <i>Enterocytozoon bienewisi</i> in patients with HIV infection. <i>Aids</i> , 1997, 11, 1603-1610.	1.0	64
82	In situ detection of human cytomegalovirus DNA in gastrointestinal biopsies from AIDS patients by means of various PCR-derived methods. <i>Journal of Virological Methods</i> , 1996, 56, 125-137.	1.0	20
83	Crescentic Glomerulonephritis and Crystals within Glomerular Capillaries in an AIDS Patient Treated with Foscarnet. <i>American Journal of Nephrology</i> , 1995, 15, 256-259.	1.4	17